Product Code: CMI3790
Human immunoglobulin for intravenous injection (IVIG) has the capacity of proving passive immunity and anti-inflammatory, immunomodulatory effect which results in better treatment and prognosis of severe infections such as COVID-19. The IgG antibodies extracted from recovered patients of COVID- 19 are expected to boost the immune response in newly infected patients, leading to a reduction in the treatment duration. Hence, the combination of the immune IgG antibodies as human immunoglobulin for intravenous injection (IVIG) with antiviral drugs can offer short-term and medium-term solutions against COVID-19. Hence, the COVID-19 outbreak is expected to increase demand for human immunoglobulin (pH4) for intravenous injection which is expected to boost the growth of human immunoglobulin (pH4) for intravenous injection (COVID-19) market.
Market Dynamics
The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to enhance their market presence is expected to propel the market growth during the forecast period. For instance, in January 2020, ADMA Biologics, Inc., a manufacturer and distributor of plasma-derived biologics, entered a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA's Immune Globulin (IG) manufacturing process. Under this agreement ADMA Biologics, Inc. will maximize the revenue per liter of plasma fractionated in its plant by selling the fractioned plasma to a third party to develop their own therapeutic products under their own licensed manufacturing processes.
Key features of the study:
- This report provides in-depth analysis of the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, disease indication up-gradation, market expansion, and marketing tactics
- The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market
Detailed Segmentation:
- Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Type:
- Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Disease Indication:
- COVID-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- Kawasaki Disease
- B Chronic lymphocytic Leukemia(B-CLL)
- Others
- Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Region:
- North America
- By Type
- IgG
- IgA
- IgM
- By Disease Indication:
- COVID-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- Kawasaki Disease
- B Chronic lymphocytic Leukemia(B-CLL)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.S.
- Canada
- Latin America
- By Type
- IgG
- IgA
- IgM
- By Disease Indication:
- COVID-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- Kawasaki Disease
- B Chronic lymphocytic Leukemia(B-CLL)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Type
- IgG
- IgA
- IgM
- By Disease Indication:
- COVID-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- Kawasaki Disease
- B Chronic lymphocytic Leukemia(B-CLL)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Type
- IgG
- IgA
- IgM
- By Disease Indication:
- COVID-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- Kawasaki Disease
- B Chronic lymphocytic Leukemia(B-CLL)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Type
- IgG
- IgA
- IgM
- By Disease Indication:
- COVID-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- Kawasaki Disease
- B Chronic lymphocytic Leukemia(B-CLL)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Type
- IgG
- IgA
- IgM
- By Disease Indication:
- COVID-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- Kawasaki Disease
- B Chronic lymphocytic Leukemia(B-CLL)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Takeda Pharmaceutical Company Limited*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Baxter International Inc.
- CSL Behring
- Bayer AG
- Grifols, S.A.
- Octapharma AG
- Shanghai RAAS Blood Products Co., Ltd.
- Hualan Biological Engineering Inc.
- China Biologic Products, Inc.
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
- Boya Bio-Pharmaceutical Group Co., Ltd.
- ADMA Biologics, Inc.
- Sinopharm Group Co., Ltd.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Industry Trend
- Merger and Acquisitions
- New Disease Indication Approvals/Launch
- Promotion and Marketing Initiatives
- PEST Analysis
1. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Type, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- IgG
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- IgA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- IgM
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
2. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Disease Indication, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- COVID-19
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Primary Immunodeficiency Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Immune-mediated Thrombocytopenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Kawasaki Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- B Chronic lymphocytic Leukemia(B-CLL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
3. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
4. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Region, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- North America
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa
5. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Takeda Pharmaceutical Company Limited
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Baxter International Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- CSL Behring
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Grifols, S.A.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Octapharma AG
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Shanghai RAAS Blood Products Co., Ltd.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Hualan Biological Engineering Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- China Biologic Products, Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Boya Bio-Pharmaceutical Group Co., Ltd.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- ADMA Biologics, Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sinopharm Group Co., Ltd.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
6. Section
- References
- Research Methodology
- About Us and Sales Contact